Literature DB >> 6693048

Interobserver variability in the interpretation of epithelial ovarian cancer.

E Hernandez, B S Bhagavan, T H Parmley, N B Rosenshein.   

Abstract

The interobserver diagnostic reproducibility for epithelial ovarian neoplasia was studied. The histologic sections of 68 ovarian tumors from 34 patients were independently reviewed by two pathologists from different institutions, without knowledge of the clinical course. Each observer rendered 68 diagnoses. The interobserver agreement rate for histologic type was 60% and for histologic grade 66%. In the 23 instances in which a discrepancy in grade occurred, 5 (23%) were disagreements in the diagnosis of borderline versus malignant tumors. On analysis of the diagnostic variability with regard to histologic type, one observer (A) classified 60% of the tumors as undifferentiated, while the other observer (B) classified 59% of the tumors as serous. In an attempt to understand the reasons for the diagnostic disagreements, the observers were asked to simultaneously reexamine the material. This occurred 6 months after the initial review and they were unaware of their original diagnoses. The diagnostic differences with regard to histologic type were mainly due to (1) tumor cell heterogeneity, and (2) difficulty in discriminating between serous and undifferentiated tumors. The differences in grade were largely related to the use of different criteria. Observer A used mitotic counts while observer B used glandular pattern and its replacement by solid sheets of epithelium. Observer B consistently assigned a higher grade to the tumors. In making therapeutic decisions, clinicians should be aware of the interobserver diagnostic variability and the reasons for this variability.

Entities:  

Mesh:

Year:  1984        PMID: 6693048     DOI: 10.1016/0090-8258(84)90065-9

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Histologic evaluation of wound healing in experimental intestinal anastomoses: effects of antineoplastic agents.

Authors:  D B de Roy van Zuidewijn; P H Schillings; T Wobbes; H H de Boer
Journal:  Int J Exp Pathol       Date:  1992-08       Impact factor: 1.925

2.  AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma.

Authors:  Fan Yang; Xiaoqing Guo; Gong Yang; Daniel G Rosen; Jinsong Liu
Journal:  Mod Pathol       Date:  2011-03-25       Impact factor: 7.842

3.  Histotype classification of ovarian carcinoma: A comparison of approaches.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Michael Anglesio; Kristine Wicklund; Rex Bentley; Andrew Berchuck; Linda E Kelemen; Tayyebeh M Nazeran; C Blake Gilks; Holly R Harris; David G Huntsman; Joellen M Schildkraut; Mary Anne Rossing; Martin Köbel; Jennifer A Doherty
Journal:  Gynecol Oncol       Date:  2018-08-16       Impact factor: 5.482

4.  Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol).

Authors:  Stefan Kommoss; Dietmar Schmidt; Friedrich Kommoss; Juergen Hedderich; Philipp Harter; Jacobus Pfisterer; Andreas du Bois
Journal:  Virchows Arch       Date:  2009-01-27       Impact factor: 4.064

5.  Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.

Authors:  Catherine M Olsen; Christina M Nagle; David C Whiteman; Roberta Ness; Celeste Leigh Pearce; Malcolm C Pike; Mary Anne Rossing; Kathryn L Terry; Anna H Wu; Harvey A Risch; Herbert Yu; Jennifer A Doherty; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Shan Wang-Gohrke; Marc T Goodman; Michael E Carney; Rayna K Matsuno; Galina Lurie; Kirsten Moysich; Susanne K Kjaer; Allan Jensen; Estrid Hogdall; Ellen L Goode; Brooke L Fridley; Robert A Vierkant; Melissa C Larson; Joellen Schildkraut; Cathrine Hoyo; Patricia Moorman; Rachel P Weber; Daniel W Cramer; Allison F Vitonis; Elisa V Bandera; Sara H Olson; Lorna Rodriguez-Rodriguez; Melony King; Louise A Brinton; Hannah Yang; Montserrat Garcia-Closas; Jolanta Lissowska; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Penelope M Webb
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678

6.  Intraobserver reproducibility in assigning brain tumors to classes in the World Health Organization diagnostic scheme. The Childhood Brain Tumor Consortium.

Authors: 
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

7.  Type-specific cell line models for type-specific ovarian cancer research.

Authors:  Michael S Anglesio; Kimberly C Wiegand; Nataliya Melnyk; Christine Chow; Clara Salamanca; Leah M Prentice; Janine Senz; Winnie Yang; Monique A Spillman; Dawn R Cochrane; Karey Shumansky; Sohrab P Shah; Steve E Kalloger; David G Huntsman
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

8.  Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer.

Authors:  S M Scholl; C H Bascou; V Mosseri; R Olivares; H Magdelenat; T Dorval; T Palangié; P Validire; P Pouillart; E R Stanley
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

9.  Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Authors:  Brent D Kerger; Robert C James; David A Galbraith
Journal:  Front Genet       Date:  2014-05-30       Impact factor: 4.599

10.  Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America.

Authors:  Peter F Rambau; Martin Köbel; Derek Tilley; Alex Mremi; Robert Lukande; William Muller
Journal:  Diagn Pathol       Date:  2020-07-16       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.